laniquidar
Small moleculeexperimental
Laniquidar (INN) is a third generation P-glycoprotein inhibitor that underwent clinical studies for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). It has been discontinued because of its low bioavailability and a high variability with how the patients responded to the drug. — Wikipedia
Clinical trial activity
1 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2001 (NCT00028873)
Timeline
2000s
- Jan 1, 2001
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Bile salt export pumpINHIBITOR
ABCB11 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
COC(=O)c1cnc2n1CCc1ccccc1C2=C1CCN(CCc2ccc(OCc3ccc4ccccc4n3)cc2)CC1- Mol. weight
- 584.72 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaLaniquidar ↗
- ChEMBLCHEMBL539378 ↗
Also known as
- 11c-laniquidar
- laniquidar
- laniquidar
- laniquidar
- laniquidar
- laniquidar
- r101933
- r 101933
- r-101933
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00028873 | Phase 2 | Sep 1, 2001 | Centre Georges Francois Leclerc, European Organisation for Research and Treatment of Cancer, Free University of Brussels, Medical Oncology Centre of Rosebank |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Centre Georges Francois Leclerc | Academic/Hospital | 1 | 0 | 1 | 2001 |
| European Organisation for Research and Treatment of Cancer | Academic/Hospital | 1 | 1 | 1 | 2001 |
| Free University of Brussels | Academic/Hospital | 1 | 0 | 1 | 2001 |
| Medical Oncology Centre of Rosebank | Academic/Hospital | 1 | 0 | 1 | 2001 |
4 organizations
Page 1 / 1